{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:08:56Z","timestamp":1790323736890,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007168.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T00:00:00Z","timestamp":1373587200000}}],"reference-count":56,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007168.pub3","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T13:21:17Z","timestamp":1373635277000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Julian","family":"Tam","sequence":"first","affiliation":[{"name":"University of Saskatchewan; Division of Respirology, Critical Care, and Sleep Medicine. Department of Medicine; 5th Floor Ellis Hall 103 Hospital Drive Saskatoon SK Canada S7N 0W8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F","family":"Nash","sequence":"additional","affiliation":[{"name":"Birmingham Heartlands Hospital; Department of Respiratory Medicine; Bordesley Green East Birmingham UK B9 5SS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Department of Pediatrics; 555 University Avenue Toronto ON Canada M5G 1XB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[{"name":"St Michael's Hospital; Division of Respirology; Toronto ON Canada M5B 1W8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stephenson","sequence":"additional","affiliation":[{"name":"St Michael's Hospital; Division of Respirology; Toronto ON Canada M5B 1W8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,12]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1378\/chest.127.1.308","article-title":"A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis","volume":"127","author":"Bishop","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/030006059502300409","article-title":"The management of cystic fibrosis with carbocysteine lysine salt: single-blind comparative study with ambroxol hydrochloride","volume":"23","author":"Caramia","year":"1995","journal-title":"The Journal of International Medical Research"},{"issue":"8","key":"10.1002\/14651858.CD007168.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/2047-783X-14-8-352","article-title":"A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis","volume":"14","author":"Dauletbaev","year":"2009","journal-title":"European Journal of Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD007168.pub3-BIB0004|cit4","first-page":"82","article-title":"A double-blind study of the use of acetylcysteine in patients with cystic fibrosis","volume":"32","author":"Howatt","year":"1966","journal-title":"University of Michigan Medical Center Journal"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0005|cit5","first-page":"40","article-title":"Controlled trial of oral N-acetylcysteine in cystic fibrosis","volume":"18","author":"Mitchell","year":"1982","journal-title":"Australian Paediatric Journal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0006|cit6","unstructured":"Ratjen F Posselt HG W\u00f6nneR St\u00f6ver B Bender SWJW A double-blind placebo controlled trial with ambroxol and N-Acetylcysteine for mucolytic treatment in cystic fibrosis [abstract] Proceedings of the 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England 1984 3.04"},{"issue":"4","key":"10.1002\/14651858.CD007168.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00441781","article-title":"A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis","volume":"144","author":"Ratjen","year":"1985","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Stafanger G Garne S Howitz P Koch C Effect of peroral N-acetylcysteine in patients with cystic fibrosis and primary cilia dyskinesia [abstract] Proceedings of 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1986 Sept 1-2; Budapest, Hungary 1986 129","DOI":"10.1183\/09031936.93.01020161"},{"issue":"2","key":"10.1002\/14651858.CD007168.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.93.01020161","article-title":"The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"1","author":"Stafanger","year":"1988","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0010|cit10","first-page":"R(c)29","article-title":"The effect of oral Nacteylcysteine on lung function CF patients [abstract]","volume":"74","author":"Stafanger","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1183\/09031936.93.02030234","article-title":"N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility","volume":"2","author":"Stafanger","year":"1989","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0012|cit12","unstructured":"Weller P Ingram D Preece M Matthew D A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract] Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands 1979 58"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/thx.35.1.42","article-title":"Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis","volume":"35","author":"Weller","year":"1980","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD007168.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1183\/09031936.02.00025802","article-title":"Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis","volume":"19","author":"App","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S69 Abstract no","DOI":"10.1016\/S1569-1993(12)60220-3","article-title":"Inhaled GSH tolerability in patients with cystic fibrosis (CF) [abstract]","volume":"11 Suppl 1","author":"Casale","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jama.1967.03120010059010","article-title":"Bronchial lavage in cystic fibrosis. A comparison of agents","volume":"199","author":"Cezeaux","year":"1967","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1099-0496(199609)22:3<161::AID-PPUL4>3.0.CO;2-S","article-title":"Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase","volume":"22","author":"Dasgupta","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1542\/peds.55.1.96","article-title":"Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride)","volume":"55","author":"Dietzsch","year":"1975","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0019|cit19","first-page":"122","article-title":"Oral acetylcysteine in cystic fibrosis. A co-operative study","volume":"111","author":"Gotz","year":"1980","journal-title":"European Journal of Respiratory Disease. Supplement"},{"issue":"7","key":"10.1002\/14651858.CD007168.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200308-1104OC","article-title":"Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis","volume":"169","author":"Griese","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000195725","article-title":"Immediate effect of various treatments on lung function in infants with cystic fibrosis","volume":"55","author":"Maayan","year":"1989","journal-title":"Respiration"},{"issue":"7","key":"10.1002\/14651858.CD007168.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/ajrccm.165.7.2105032","article-title":"Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis","volume":"165","author":"Snyder","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007168.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/ptj\/56.9.999","article-title":"Bronchial drainage with aerosol medications in cystic fibrosis","volume":"56","author":"Tecklin","year":"1976","journal-title":"Physical Therapy"},{"issue":"Suppl 29","key":"10.1002\/14651858.CD007168.pub3-BIB0024|cit24","first-page":"295","article-title":"Phase 2 trial of high-dose oral N-Acetylcysteine as a systemic antioxidant and inhibitor of lung inflammation in CF [abstract]","volume":"41","author":"Tirouvanziam","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S11, Abstract n","DOI":"10.1016\/S1569-1993(12)60034-4","article-title":"Inhaled glutathione in cystic fibrosis [abstract]","volume":"11 Suppl 1","author":"Griese","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0026|cit26","unstructured":"Griese M Kappler M Eismann C Ballmann M Junge S Rietschel E Inhalation treatment with glutathione in patients with cystic fibrosis: a randomised controlled trial American Journal of Respiratory and Critical Care Medicine 2013 2013 April 30 [Epub ahead of print]"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0027|cit27","first-page":"280 Abstract no","article-title":"A multi-center, phase IIB, randomized, placebo-controlled, double-blind study of the effects of N-acetylcysteine (NAC) on redox changes and lung inflammation in cystic fibrosis patients [abstract]","volume":"46 Suppl 34","author":"Tirouvanziam","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S18, Abstract n","DOI":"10.1016\/S1569-1993(11)60089-1","article-title":"The effect of N-acetylcysteine on the visco-elasticity of sputum of cystic fibrosis patients [abstract]","volume":"10 Suppl 1","author":"Daele","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD007168.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1164\/ajrccm\/144.5.1202","article-title":"Lung function testing: selection of reference values and interpretative strategies","volume":"144","author":"American Thoracic Society","year":"1991","journal-title":"American Review of Respiratory Disease"},{"issue":"Suppl","key":"10.1002\/14651858.CD007168.pub3-BIB0030|cit30","first-page":"217","article-title":"Toxicological, pharmacokinetic and metabolic studies on acetylcysteine","volume":"111","author":"Bonanomi","year":"1980","journal-title":"European Journal of Respiratory Disease"},{"issue":"3-4","key":"10.1002\/14651858.CD007168.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02009054","article-title":"Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of alpha 1-proteinase inhibitor by N-acetyl cysteine, glutathione and methionine","volume":"22","author":"Borregaard","year":"1987","journal-title":"Agents Actions"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0032|cit32","unstructured":"Cystic Fibrosis Foundation Annual Report CFF Annual Report 2007"},{"issue":"10","key":"10.1002\/14651858.CD007168.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970-1989","volume":"143","author":"Corey","year":"1996","journal-title":"American Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007168.pub3-BIB0034|cit34","first-page":"73","article-title":"No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid","volume":"70","author":"Cotgreave","year":"1987","journal-title":"European Journal of Respiratory Disease"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/sim.1205","article-title":"Meta-analysis combining parallel and cross-over clinical trials.I: Continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007168.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/thx.2007.082768","article-title":"Lung clearance index in CF: a sensitive marker of lung disease severity","volume":"63","author":"Davies","year":"2008","journal-title":"Thorax"},{"issue":"5","key":"10.1002\/14651858.CD007168.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic Fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.1999.tb01265.x","article-title":"Systematic review of N-acetylcysteine in cystic fibrosis","volume":"88","author":"Duijvestijn","year":"1999","journal-title":"Acta Paediatrica"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007168.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD007168.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0043|cit43","first-page":"86","article-title":"MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions","volume":"31","author":"Henke","year":"2004","journal-title":"American J ournal of R espiratory C ell and M olecular B iology"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatric Respiratory Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD007168.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0046|cit46","unstructured":"Higgins JPT Altman DG Sterne JAC behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127","article-title":"Recombinant human deoxyribonuclease for cystic fibrosis","author":"Jones","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD007168.pub3-BIB0048|cit48","first-page":"438s","article-title":"Determination of the mode of action of a novel mucolytic agent Nacystelyn","volume":"6","author":"Marriott","year":"1993","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/ars.2006.8.681","article-title":"Current concepts of redox signaling in the lungs","volume":"8(3-4)","author":"Rahman","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0050|cit50","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0051|cit51","first-page":"721","article-title":"The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine","volume":"90","author":"Sheffner","year":"1964","journal-title":"American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD007168.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.200212-1437OC","article-title":"In Vivo and In Vitro Effects of Macrolide Antibiotics on Mucus Secretion in Airway Epithelial Cells","volume":"168","author":"Shimizu","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007168.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanziam","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD007168.pub3-BIB0054|cit54","first-page":"77","article-title":"Acetylcysteine","volume-title":"Drugs in Bronchial Mucology","author":"Ventresca","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD007168.pub3-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub2","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007168.pub3-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007168.pub2","article-title":"Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis","author":"Nash","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007168.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T21:32:23Z","timestamp":1711229543000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007168.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,12]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007168.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,12]]}}}